ArticleClinics (Sao Paulo, Brazil)2026

Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system.

Zhixun Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.